NYSE: $ABBV Breaking News in Dermatology AbbVie has recently shared promising topline results from their Phase 3 INTREPID trial, which evaluated the efficacy and safety of lutikizumab in patients living with moderate to severe hidradenitis suppurativa (HS). What the Trial Results Show The study marks a significant milestone for patients who have previously been treated…